Lochner, Martin; Thompson, Andrew James (2016). The muscarinic antagonists scopolamine and atropine are competitive antagonists at 5-HT3 receptors. Neuropharmacology, 108, pp. 220-228. Elsevier 10.1016/j.neuropharm.2016.04.027
|
Text (Accepted Manuscript)
1-s2.0-S0028390816301678-main.pdf - Accepted Version Available under License Creative Commons: Attribution (CC-BY). Download (2MB) | Preview |
|
|
Text (Printed Paper)
Neuropharm2016.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
Scopolamine is a high affinity muscarinic antagonist that is used for the prevention of post-operative nausea and vomiting. 5-HT3 receptor antagonists are used for the same purpose and are structurally related to scopolamine. To examine whether 5-HT3 receptors are affected by scopolamine we examined the effects of this drug on the electrophysiological and ligand binding properties of 5-HT3A receptors expressed in Xenopus oocytes and HEK293 cells, respectively. 5-HT3 receptor-responses were reversibly inhibited by scopolamine with an IC50 of 2.09 μM. Competitive antagonism was shown by Schild plot (pA2 = 5.02) and by competition with the 5-HT3 receptor antagonists [3H]granisetron (Ki = 6.76 µM) and G-FL (Ki = 4.90 µM). The related molecule, atropine, similarly inhibited 5-HT evoked responses in oocytes with an IC50 of 1.74 µM, and competed with G-FL with a Ki of 7.94 µM. The reverse experiment revealed that granisetron also competitively bound to muscarinic receptors (Ki = 6.5 µM). In behavioural studies scopolamine is used to block muscarinic receptors and induce a cognitive deficit, and centrally administered concentrations can exceed the IC50 values found here. It is therefore possible that 5-HT3 receptors are also inhibited. Studies that utilise higher concentrations of scopolamine should be mindful of these potential off-target effects.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
08 Faculty of Science > Department of Chemistry, Biochemistry and Pharmaceutical Sciences (DCBP) 04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Biochemistry and Molecular Medicine |
UniBE Contributor: |
Lochner, Martin, Thompson, Andrew James |
Subjects: |
500 Science > 570 Life sciences; biology 500 Science > 540 Chemistry 600 Technology > 610 Medicine & health |
ISSN: |
0028-3908 |
Publisher: |
Elsevier |
Funders: |
[42] Schweizerischer Nationalfonds ; [UNSPECIFIED] British Heart Foundation |
Language: |
English |
Submitter: |
Martin Lochner |
Date Deposited: |
15 Jun 2016 11:46 |
Last Modified: |
05 Dec 2022 14:56 |
Publisher DOI: |
10.1016/j.neuropharm.2016.04.027 |
PubMed ID: |
27108935 |
BORIS DOI: |
10.7892/boris.82240 |
URI: |
https://boris.unibe.ch/id/eprint/82240 |